ExLibris header image
SFX Logo
Title: Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses
Source:

Proceedings of the National Academy of Sciences of the United States of America [0027-8424] Koya, R C yr:2010


Collapse list of basic services Basic
Full text
Full text available via PubMed Central
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Comin Anduix, B. "The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations." Clinical cancer research 16.24 (2010): 6040-6048. Link to SFX for this item
2. Voss, R. "Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells." Blood 115.25 (2010): 5154-5163. Link to SFX for this item
3. Minasyan, A. "BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy." Cancer research 72.16 (2012): 3928-3937. Link to SFX for this item
4. Kammula, Steven T. "Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen." Blood 114.3 (2009): 535-546. Link to SFX for this item
5. Wargo, Jennifer A. "BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma." Clinical cancer research 19.5 (2013): 1225-1231. Link to SFX for this item
6. Das, Susanta K. "Highly efficient THG in TiO(2) nanolayers for third-order pulse characterization." Optics express 19.18 (2011): 16985-16995. Link to SFX for this item
7. Nazarian, R. "Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation." Nature 468.7326 (2010): 973-977. Link to Full Text for this item Link to SFX for this item
8. Lo, Agnes S Y S. "Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors." Clinical cancer research 16.10 (2010): 2769-2780. Link to SFX for this item
9. Sndergaard, Jonas N. "Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032." Journal of Translational Medicine 8.1 (2010): 39-39. Link to Full Text for this item Link to SFX for this item
10. Valitutti, S. "Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition." Immunology today 18.6 (1997): 299-304. Link to Full Text for this item Link to SFX for this item
11. Marais, R. "Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin." Cancer research 65.23 (2006): 10686-91. Link to SFX for this item
12. Morgan, Richard A. "Cancer regression in patients after transfer of genetically engineered lymphocytes." Science 314.5796 (2006): 126-9. Link to SFX for this item
13. Johannessen, Cory M. "COT drives resistance to RAF inhibition through MAP kinase pathway reactivation." Nature 468.7326 (2010): 968-972. Link to Full Text for this item Link to SFX for this item
14. Liu, C. "BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice." Clinical cancer research 19.2 (2013): 393-403. Link to SFX for this item
15. Restifo, Nicholas P. "Adoptive immunotherapy for cancer: harnessing the T cell response." Nature reviews. Immunology 12.4 (2012): 269-281. Link to SFX for this item
16. Bollag, Hirth P. "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma." Nature 467.7315 (2010): 596-599. Link to Full Text for this item Link to SFX for this item
17. Kudchadkar, R. "Targeting Mutant BRAF in Melanoma: Current Status and Future Development of Combination Therapy Strategies." The cancer journal 18.2 (2012): 124-131. Link to SFX for this item
18. Sosman, Jeffrey A. "Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib." The New England journal of medicine 366.8 (2012): 707-714. Link to SFX for this item
19. Wallis, S. "Merkel cell carcinoma." Journal of Nepal Medical Association 49.178 (2010): 151-154. Link to SFX for this item
20. Shen, X. "Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length." Journal of immunotherapy 30.1 (2006): 123-9. Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.